NCT06897670Recruiting
Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS). By comparing brain activity across different groups and relating it to symptom severity, this study aims to improve our understanding of how these conditions affect the brain.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 20 Mar 2025
- Start date
- 26 Mar 2025
- Primary completion date
- 30 Mar 2028
- Lead sponsor
- Mayo Clinic
- Diseases
- Depression, Bipolar disorder
- NCT number
- NCT06897670
What you commit to
- Study type: Observational
- Planned participants: 200
- From 26 Mar 2025 to the primary completion date, 30 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active primary psychotic or substance use disorders (except nicotine dependence) within the past year
- Any severe or unstable medical condition that could interfere with participation or data collection
- Any active neurological condition (including seizure disorder, traumatic brain injury, stroke) that could affect cognitive functioning or brain imaging results
- Healthy control
- o Any past or current psychiatric or cognitive disorder
- Major depressive disorder (MDD):
- Diagnosis of bipolar disorder or schizophrenia.
- Brain stimulation therapy within the past 3 months.
- Bipolar disorder:
- o Diagnosis of schizophrenia or schizoaffective disorder.
- Mild Cognitive Impairment (MCI):
- Diagnosis of dementia.
- Significant cognitive impairment preventing understanding or completion of study tasks.
Other
- General Exclusion Criteria (across all diagnostic groups):
- Inability to comply with study procedures, including cognitive testing, fNIRS assessment, or other assessments required by the protocol
- Pregnant women will be excluded due to potential physiological changes that could affect study outcomes
- Specific Exclusion Criteria (for diagnostic groups):
Who the study is looking for
- General Inclusion Criteria (across all diagnostic groups):
- 18 years and older
- Ability to provide written informed consent
- Adequate cognitive and language abilities to understand and complete study tasks, including clinical assessments and fNIRS procedures
- Confirmed clinical diagnosis of major depressive disorder, bipolar disorder, or mild cognitive impairment (MCI)
- Stable psychiatric or cognitive condition, without acute episodes requiring immediate intervention
- Specific Inclusion Criteria (for diagnostic groups):
- Healthy control
- o No past or current psychiatric or cognitive disorder
- Major depressive disorder (MDD):
- Diagnosis of major depressive disorder, confirmed through clinical evaluation.
- No history of bipolar disorder or psychotic symptoms.
- Bipolar disorder:
- o Diagnosis of bipolar disorder I or II, confirmed through clinical evaluation.
- Mild Cognitive Impairment (MCI):
- Pre-existing clinical diagnosis of mild cognitive impairment, supported by neuropsychological testing and/or MRI, PET scan data.
- No history of major psychiatric disorders, such as major depression, bipolar disorder or schizophrenia.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.